hepatomiR cACLD Study
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorKarl Landsteiner University of Health Sciences
About this trial
This study looks to gather data on hepatomiR, a CE-certified test already intended for gauging liver-related outcomes, in order to define a cut-off regarding specific decompensation events (ascites, variceal hemorrhage, hepatic encephalopathy) in chronic liver disease (CLD). Based on these data, it is aimed to advance the current understanding of factors driving decompensation, with potential repercussions for future risk management and therapy.
Eligibility criteria
Qualifiers
Age ≥ 18 years
Chronic liver disease (more than 6 months)
LSM ≥ 10 kPa
Outpatient at the Clinical Department of Internal Medicine II, University Hospital St. Pölten
Disqualifiers
Age older than 18 years
Pregnancy
Primary hepatic malignancy (hepatocellular carcinoma, cholangiocarcinoma) with portal invasion and/or extrahepatic spread
Trial design
Treatments tested in this trial
- hepatomiR
Treatment groups
156 Participants
are divided into 1 treatment groupSponsors and collaborators
Karl Landsteiner University of Health Sciences
Lead sponsor
University Hospital St. Polten
Collaborator
Source ClinicalTrials.gov